Psychometric Properties of the Turkish Version of the Modified Mini Mental State Examination

March 11, 2025 updated by: Eastern Mediterranean University

Investigation of Psychometric Properties of the Turkish Version of the Modified Mini Mental State Examination in Typically Developing Children and Children With Neurodevelopmental Disorders

One of the most commonly used screening tests for the mental status of adults is the Standardized Mini Mental State Examination (MMSE). The MMSE is designed to screen for cognitive dysfunction, assess the severity of impairments, and identify changes over time. In the country of the researchers, the Turkish adaptation of the MMSE for children has not been done and the validity and reliability of the Turkish version has not been demonstrated. This paper aims to investigate the pschiatric features of the MMSE for Turkish pediatric population.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

Cerebral Palsy progresses with neurosensory, behavioral and cognitive disorders, especially restrictive adaptive behaviors, and a wider range of symptoms and functional disorders (1). Cognitive functions are all the brain functions required to receive stimuli from the outside and inside, select stimuli, create responses and coordinate with the environment (2). During childhood, cognitive functions can be negatively affected by many diseases, conditions or health problems. Evaluation of cognitive functions is important to determine whether cognitive abilities deviate from normal, to treat and monitor them. For this reason, many different tests are used in different age groups. These are; Montreal cognitive assessment (MoCA), Raven matrices, Wechsler adult intelligence scale (WAIS), Rey-identity and response memory test, Bender visual motor perception test, Delis-kaplan verbal reasoning test (D-KEFS), Stroop Test and Verbal memory tests are some of them. These tests are usually specific to their fields and may require trained professionals for long application periods. One of the most commonly used screening tests for adults is the Standardized Mini Mental State Examination (MMSE). The MMSE is designed to screen for cognitive dysfunctions, assess the severity of the disorders, and determine changes over time. The MMSE was developed by Folstein and colleagues (3) to rapidly assess cognitive functions. It consists of five sections: orientation, registration, attention and calculation, recall, and language, and is scored out of 30 points. Some of the existing screening tools used in childhood are limited in their use due to their reliance on parental reports, unknown correlations with general intelligence, the need for motor skills, literacy, and lack of sensitivity to developmental change. Therefore, it has been determined that there is a need for low-cost, rapidly administerable short cognitive screening tools that will allow rapid assessment of a wide range of cognitive domains in childhood. In this context, pediatric versions of the MMSE have begun to be used in various countries, such as Australia (4), India (5), Niger (6), Spain (7), and the USA (8). However, the psychometric properties of the MMSE in children with CP have only been reported in Brazil by Moura et al. (9). The Turkish adaptation of the MMSE has not been made for children and the validity and reliability of the Turkish version has not been demonstrated.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
397

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Cyprus
      • Famagusta, Cyprus, 99628
        • Zehra Güçhan Topcu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Children aged between the years of 5 and 18 who were diagnosed with neurodevelopmental disorders (Attention Deficit and Hyperactivity Disorder, Specific Learning Disorder, Autism Spectrum Disorder, Motor Disorders (Spastic SP)

Description

Inclusion Criteria:

  • Between the ages of 5-18,
  • Children diagnosed with neurodevelopmental disorders (Attention Deficit and Hyperactivity Disorder, Specific Learning Disorder, Autism Spectrum Disorder, Motor Disorders (Spastic SP)
  • Children who can understand and apply Turkish commands

Exclusion Criteria:

Those with have serious hearing and speech problems

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Modified Mini Mental State Examination
Time Frame: at baseline and on the 7th day from the baseline
Its scoring is between 0-12. For attention; it consists of 2 sub-items as counting forward and backward. The total score is between 0-7. For sensory perception; the child will be asked to name 3 known objects (pen, watch, glasses). Its scoring is between 0-3. For recall; the child will be asked to show and explain the previous 3 objects (pen, watch, glasses). Its scoring is between 0-3. For language; first, the child will be asked to name the 5 determined body parts (hand, foot, knee, nose, ear), second, they will be asked to carry out a 3-stage command, third, they will be asked to repeat a tongue twister, fourth, they will be asked to read and apply the shown text (close their eyes), fifth, they will be asked to write their name and finally they will be asked to draw the shown shape. Scoring ranges from 0 to 12. The highest score that can be obtained from the Modified MMSE is 37. Application time is between 8-15 minutes.
at baseline and on the 7th day from the baseline

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Colored Progressive Matrices Test (RPM)
Time Frame: at baseline and on the 7th day from the baseline
In each matrix consisting of meaningless shapes in parts called A, AB and B, there is a shape with a missing part. It will be asked to find the correct one from the 6 options that complete the missing part in the bottom part. It will receive 1 point for each correct answer.
at baseline and on the 7th day from the baseline
Functional Independence Measure for Children (WeeFIM)
Time Frame: at baseline and on the 7th day from the baseline
It consists of 6 sections including self-care (eating, washing hands and face, brushing teeth, toileting, bathing and dressing), sphincter control (bladder and bowel habits), transfer (transfer to toilet, shower and chair), locomotion (walking, crawling, going up and down stairs), communication (understanding and expressing) and social status (social relationships, problem solving and memory) and contains a total of 18 items. The family will be asked to score each item in these sections from 1 to 7 according to whether the individual received help while performing the function, whether he/she did it on time or whether an assistive device was required. The "Self-Care" subscale will be used in this study. The child's level of independence in daily life will be recorded by asking 6 questions here.
at baseline and on the 7th day from the baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Eastern Mediterranean University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Emine HANDAN TÜZÜN, Prof., Eastern Mediterranean University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 1, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 1, 2025

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 1, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 4, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 4, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 25, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 25, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 11, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • ETK000000001

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings